Intuitive Surgical, Inc. $ISRG Stake Boosted by Plato Investment Management Ltd

Key Points

• Plato Investment Management Ltd increased its stake in Intuitive Surgical by 31.7%, holding 10,330 shares worth $5,172,000 as of the end of the most recent quarter.
• Analysts have set a consensus price target of $595.95 for Intuitive Surgical, with an average rating of "Moderate Buy" from 13 investment analysts.
• Insider activity revealed significant sales, including Gary S. Guthart selling 29,360 shares for approximately $13.9 million, reducing his ownership by nearly 60%.

Plato Investment Management Ltd boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 31.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,330 shares of the medical equipment provider's stock after purchasing an additional 2,486 shares during the quarter. Plato Investment Management Ltd's holdings in Intuitive Surgical were worth $5,172,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Chilton Capital Management LLC boosted its holdings in shares of Intuitive Surgical by 614.3% in the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 43 shares during the period. Global Financial Private Client LLC lifted its holdings in Intuitive Surgical by 253.3% in the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 38 shares during the last quarter. Elite Financial Inc. acquired a new position in Intuitive Surgical in the first quarter valued at approximately $26,000. LFA Lugano Financial Advisors SA bought a new position in shares of Intuitive Surgical during the first quarter valued at approximately $30,000. Finally, TD Capital Management LLC grew its holdings in shares of Intuitive Surgical by 300.0% during the first quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 45 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on ISRG. Evercore ISI upped their price objective on Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Zacks Research downgraded shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $615.00 price objective on shares of Intuitive Surgical in a report on Tuesday, August 19th. Piper Sandler reiterated an "overweight" rating and issued a $595.00 price objective (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Finally, BTIG Research boosted their target price on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Thirteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $595.95.

Intuitive Surgical Trading Down 0.5%

Intuitive Surgical stock opened at $467.54 on Wednesday. The stock has a market cap of $167.60 billion, a price-to-earnings ratio of 65.21, a PEG ratio of 4.93 and a beta of 1.61. The company's 50-day moving average price is $491.12 and its two-hundred day moving average price is $510.92. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business's revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter last year, the business earned $1.78 earnings per share. Research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Gary S. Guthart sold 29,360 shares of Intuitive Surgical stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the transaction, the insider directly owned 19,827 shares of the company's stock, valued at $9,368,059.23. The trade was a 59.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the sale, the executive vice president directly owned 353 shares of the company's stock, valued at $173,845.44. The trade was a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,224 shares of company stock worth $21,716,492 over the last 90 days. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.